Procaps Group, S.A EBITDA 2020-2023 | PROCF
Procaps Group, S.A ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Procaps Group, S.A Annual EBITDA
(Millions of US $) |
| 2022 |
$57 |
| 2021 |
$86 |
| 2020 |
$80 |
| 2020 |
$-1 |
| 2019 |
$54 |
| 2019 |
$-0 |
| 2018 |
$-0 |
Procaps Group, S.A Quarterly EBITDA
(Millions of US $) |
| 2023-09-30 |
$18 |
| 2023-06-30 |
$19 |
| 2023-03-31 |
$7 |
| 2022-12-31 |
$7 |
| 2022-09-30 |
$21 |
| 2022-06-30 |
$23 |
| 2022-03-31 |
$6 |
| 2021-12-31 |
$38 |
| 2021-09-30 |
$23 |
| 2021-06-30 |
$21 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$257 |
| 2020-09-30 |
$14 |
| 2020-06-30 |
$-0 |
| 2020-03-31 |
$-0 |
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.125B |
$0.410B |
|
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.
|
